Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH-HHT: Pomalidomide for HHT Bleeding
NCT03910244Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Oct 2019
- Primary completion
- Sep 2023
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Pomalidomide with Placebo (2 arms). Primary endpoint: Epistaxis Severity Score at 24 weeks. Started Oct 2019; status: completed.
02
Drugs
pomalidomide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT03910244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910244.